Second Quarter 2018 Financial Results

Second Quarter 2018 Financial Results

Jerusalem, Israel - August 22, 2018

-- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing

M-001, a universal flu vaccine candidate, today announced its financial results for the quarter ended June 30, 2018.

Second Quarter 2018 Financial Summary

Results are in New Israel Shekels (NIS) and convenience translation

to $US is provided using the exchange rate of 3.65 (NIS/$US) as at June 30, 2018.

As of June 30, 2018, BiondVax had cash

and cash equivalents of NIS 37.1 million ($10.1 million) as compared to NIS 36.6m as of March 30, 2018. Expenses are related to

execution of planned ongoing operations including the launch of a pivotal, clinical efficacy, Phase 3 trial of the Company's

M-001 Universal Flu Vaccine candidate, and construction of a mid-size commercial manufacturing facility.

BiondVax (NASDAQ: BVXV) is a Phase 3 clinical

stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide

multi-season protection against current and future, seasonal and pandemic influenza virus strains. BiondVax's proprietary

technology utilizes a unique combination of conserved and common influenza virus peptides, activating both arms of the immune system

for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 human clinical trials, covering

698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. Please visit www.biondvax.com.

Joshua E. Phillipson

Forward Looking Statements

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as

"expect," "believe," "intend," "plan," "continue," "may,"

"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These

forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to

certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results

to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include,

but are not limited to, the prosecution and outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing

of receipt of regulatory approval of the new manufacturing facility its products; ability to demonstrate the efficacy and safety

of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy and expensive

process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property and patents

granted; whether our vaccine candidate will successfully advance through the clinical trial process on a timely basis, or

at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies;

the adequacy of available cash resources and the ability to raise capital when needed. More detailed information about the

risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on

Form 20-F for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission, or SEC, which is available

on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.

We undertake no obligation to revise or update any forward-looking statement for any reason.

** Tables to Follow **

In thousands, except per share data

STATEMENTS OF COMPREHENSIVE

In thousands, except per share data